Insider · CIK 0001855980
Michael Secora
Files at RXRX (RECURSION PHARMACEUTICALS, INC.). First filing Nov 14, 2024, latest Nov 14, 2024.
Michael Secora files SEC Form 4 as CFO at RXRX (RECURSION PHARMACEUTICALS, INC.). Since Nov 14, 2024, Michael Secora has reported 0 open-market buys worth $0 and 1 open-market sell worth $230k, the latest filed on Nov 14, 2024.
A track record needs three past buys with six months of prices behind them; Michael Secora has 0, so none is measured yet.
The newest scored trade: sold $230k of RXRX on Nov 12, 2024, filed Nov 14, 2024, scored 15 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RXRX: RECURSION PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | RECURSION PHARMACEUTICALS, INC. | $230k 30,000 shares | -2% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 17, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | 5,000 0.00% of outstanding | $33k | Jan 17, 2025 | $654k |
| Jan 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | 15,000 0.01% of outstanding | $99k | Jan 15, 2025 | $555k |
| Jan 14, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | 15,000 0.01% of outstanding | $97k | Jan 14, 2025 | $458k |
| Dec 11, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 15,000 0.01% of outstanding | $112k | Dec 11, 2024 | $631k |
| Dec 10, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 15,000 0.01% of outstanding | $116k | Dec 10, 2024 | $607k |
| Nov 13, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 15,000 0.01% of outstanding | $115k | Nov 13, 2024 | $682k |
| Nov 12, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 15,000 0.01% of outstanding | $113k | Nov 12, 2024 | $568k |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 15, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -11,937 | $6.18 | $74k | 1,487,694 | Nov 19, 2024 |
| Nov 12, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | MOption exercise Class A Common Stock10b5-1 | +39,375 | $2.22 | $87k | 1,490,256 | Nov 14, 2024 |
| Nov 12, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -15,000 | $7.64 | $115k | 1,475,256 | Nov 14, 2024 |
| Nov 13, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | MOption exercise Class A Common Stock10b5-1 | +39,375 | $2.22 | $87k | 1,514,631 | Nov 14, 2024 |
| Nov 13, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stock10b5-1 | -15,000 | $7.66 | $115k | 1,499,631 | Nov 14, 2024 |
| Nov 12, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -39,375 | $0.00 | $0 | 377,010 | Nov 14, 2024 |
| Nov 13, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -39,375 | $0.00 | $0 | 337,635 | Nov 14, 2024 |
Questions about Michael Secora
Answered from the filings on this page, as of the latest one.
Is Michael Secora buying or selling?
Not in the last 12 months. Michael Secora's latest open-market trade on SEC Form 4 was sold $230k of RXRX on Nov 12, 2024.
How did Michael Secora's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Secora has 0.
Where does Michael Secora file Form 4?
Michael Secora has filed Form 4 at RXRX (RECURSION PHARMACEUTICALS, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.